Research programme: cannabinoid CB1 receptor antagonists - Solvay

Drug Profile

Research programme: cannabinoid CB1 receptor antagonists - Solvay

Latest Information Update: 05 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Class Pyrazoles; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Psychotic disorders

Most Recent Events

  • 23 Jan 2007 Preclinical development for obesity is ongoing
  • 18 Sep 2002 Preclinical trials in Obesity in Netherlands (unspecified route)
  • 18 Sep 2002 Preclinical trials in Psychotic disorders in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top